-
ESMO 2025: MSD and Eisai’s endometrial cancer combo shows five-year durability
20 Oct 2025 16:50 GMT
… anti-PD-1 therapy plus Eisai’s oral multiple receptor tyrosine … .
Find out more
MSD and Eisai presented the data at the … by the US Food and Drug Administration (FDA) for patients with … Global Clinical Development Lead at Eisai, said: “The five-year results …
-
Weight Loss Drugs Market Set to Reach USD 50.26 Billion by 2032, Driven by Prescription Drug Adoption and Breakthrough Formulations – SNS Insider
20 Oct 2025 15:28 GMT
…
Boehringer Ingelheim International GmbH
Currax Pharmaceuticals LLC
Eisai Co., Ltd.
Eli Lilly … Inhibitors, Combination Drugs)
By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
Regional Analysis …
-
<![CDATA[Adjuvant durvalumab plus tremelimumab after RCC resection improves DFS]]>
23 Oct 2025 01:11 GMT
… Pfizer, Incyte, Dynavax, CRUK, GSK, Eisai, Merck touchIME, touchEXPERTs, Iovance, Boston … Roche, Pierre Fabre, AstraZeneca, EUSA Pharma, MSD, Ervaxx, Ipsen, Aptitude, … , Nektar Therapeutics, Covance, Immunocore, Pharmacyclics, and Aveo.
REFERENCES
1. Larkin …
-
<![CDATA[Dabrafenib Combo Confers PFS Benefit in RAI-Refractory BRAF V600-Mutant DTC]]>
22 Oct 2025 21:46 GMT
… Eisai, Inc, Coherus BioSciences, AbbVie Inc, Bicara Therapeutics, Fore Biotherapeutics, Leo Pharma …
-
<![CDATA[Treating Metastatic DTC After Radioactive Iodine Progression]]>
22 Oct 2025 21:45 GMT
… or advisory role with Merck, Eisai, Lilly, Bayer, Exelixis, Coherus Biosciences … , Tome Biosciences, EMD Serono, Ellipses Pharma, Illumina, and Nested.
References:
1 …
-
<![CDATA[Triplet Therapy Proves Feasibility, Lacks Enhanced Efficacy in Advanced ccRCC]]>
22 Oct 2025 21:45 GMT
Treatment discontinuation due to toxicity occurred in 5 patients (10%), and no treatment-related deaths were reported. Majority of patients, 96%, reported experiencing TRAEs of any grade, and 68% experienced TRAEs grade >3. Some of the most reported …
-
<![CDATA[Insurance and Tolerability Factors Considered in Recurrent RCC Treatment]]>
21 Oct 2025 02:18 GMT
… Novartis, Arrowhead Pharmaceuticals, Mirati Therapeutics, Takeda, Epizyme, and Eisai Medical Research; … Therapeutics, Calithera Biosciences, Eisai Medical Research, ONO Pharmaceutical, Eli Lilly, Oncorena … .accessdata.fda.gov/drugsatfda_docs/label…
-
<![CDATA[Bemarituzumab Regimen Prolongs Survival in Advanced Gastric/GEJ Cancer]]>
20 Oct 2025 21:26 GMT
… with Amgen, Arcus Biosciences, Astellas Pharma, AstraZeneca, BI, BeOne, Daiichi … Biosciences, Astellas Pharma, AstraZeneca, BMS/Ono, Daiichi Sankyo, Eisai, and … Astellas Pharma, AstraZeneca, Bayer, BeOne, BI, Bristol-Myers Squibb, Daiichi Sankyo, Eisai …
-
<![CDATA[ctDNA-guided atezolizumab boosts survival in muscle-invasive bladder cancer]]>
20 Oct 2025 18:05 GMT
Treatment of muscle-invasive bladder cancer (MIBC) with atezolizumab (Tecentriq), when guided by circulating tumor DNA (ctDNA), yields statistically significant benefits in disease-free survival (DFS) and overall survival (OS), according to data from the …
-
<![CDATA[Tiragolumab Regimen Misses PFS End Point in Hepatocellular Carcinoma]]>
19 Oct 2025 22:53 GMT
… in the placebo arm. Drug-related AEs were reported in … pharmaceutical companies. He serves as a Principal Investigator for Merck/Eisai … -Myers Squibb, Merck/Eisai, Pfizer, and Roche… , Chugai, Guerbet, Merck/Eisai, Novartis, Pfizer, Roche/ …
About
© 1995-2025